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Introduction {#sec1}
============

Multiple sclerosis (MS) is the most common autoimmune disease of the central nervous system, causing inflammatory demyelination and neurodegeneration ([@bib56]). Long-standing data from animal models of MS, particularly experimental autoimmune encephalomyelitis (EAE), implicate CD4^+^ T cells and their differentiation into pro-inflammatory T~H~1 and T~H~17 cells as critical to inflammatory demyelination ([@bib3]; [@bib33]). Prominent T~H~1 and T~H~17 responses are also observed in patients with MS ([@bib37]; [@bib65]). Genetic analysis in MS has largely been consistent with this data, highlighting the relevance of the immune system, particularly T cells, in promoting the development of MS ([@bib20]; [@bib27]; [@bib34]; [@bib45]; [@bib61]). This is best exemplified by the strongest genetic risk factor for MS being variants of the molecules that present antigen to T cells, namely, the human leukocyte antigen complex ([@bib6]; [@bib27]).

We have previously shown that branched *N*-glycans produced by the sequential action of the N-acetylglucosaminyl transferase enzymes Mgat1, 2, 4, and 5 play a critical role in directly limiting pro-inflammatory T cell responses and autoimmunity ([@bib1]; [@bib9]; [@bib14]; [@bib15]; [@bib23]; [@bib26]; [@bib40]; [@bib47]; [@bib52]; [@bib72]). Galectins bind the T cell receptor (TCR) and other glycoproteins at the cell surface in proportion to the branching, extension, and number of complex *N*-glycans, forming a molecular lattice that controls clustering, signaling, and endocytosis of surface receptors and transporters in a coordinated fashion. Molecularly, the galectin lattice regulates the segregation of surface glycoproteins to different membrane microdomains by acting as a brake on movement directed by intracellular actin microfilaments. For example, the galectin lattice excludes the TCR from GM3^+^ lipid rafts, while having the opposite effect on the phosphatase CD45, both by opposing the activity of actin microfilaments tethered to cytoplasmic domains of the respective proteins ([@bib9]). Functionally, *N*-glycan branching negatively regulates TCR clustering/signaling ([@bib9]; [@bib14]; [@bib26]; [@bib72]), promotes surface retention of anti-autoimmune cytotoxic T-lymphocyte antigen 4 ([@bib40]), directly inhibits T~H~1 and T~H~17 while promoting anti-autoimmune-induced T regulatory cell differentiation ([@bib1]; [@bib52]), suppresses inflammatory demyelinating disease in mice ([@bib14]; [@bib24], [@bib22]; [@bib41]), and is associated with risk of MS and other autoimmune diseases ([@bib5]; [@bib25]; [@bib44]; [@bib47]; [@bib68], [@bib69]). The extent of *N*-glycan branching is regulated by multiple signals, including alterations in gene expression (e.g., *Mgat1*, *Mgat5*) induced by signals from multiple different cell surface receptors as well as supply of metabolic precursors for the Golgi branching enzymes ([@bib1]; [@bib8]; [@bib40]; [@bib47]).

Recently, the dominant role of T cells in MS has been challenged by the potent therapeutic activity of B cell-depleting therapies in MS ([@bib60]), with the anti-CD20 monoclonal antibody ocrelizumab shown to be superior to high-dose interferon-β-1a (Rebif) at reducing relapse rates as well as displaying positive activity in progressive MS ([@bib30], [@bib31]). B cells are unique within the immune system, having both innate and adaptive immune activities, with the former exemplified by activation via pattern recognition receptors like Toll-like receptors (TLRs) and the ability to directly present antigen to CD4^+^ T cells. The therapeutic benefit of B cell depletion in MS appears to largely arise from altered innate activity and reduced antigen presentation to CD4^+^ T cells, rather than reduced B cell adaptive immune responses and autoantibody production ([@bib29]). For example, anti-CD20 therapy reduces pro-inflammatory T~H~1 and T~H~17 responses as well as B and T cell numbers but not IgG concentration, IgG index, IgG synthesis rate or oligoclonal band number in the cerebrospinal fluid of patients with MS who have been treated ([@bib2]; [@bib12]). Data in EAE also support this conclusion, with B cells promoting T~H~1 and/or T~H~17 responses as well as inflammatory demyelination via their antigen-presenting cell (APC) function rather than through antibody production ([@bib49]; [@bib51]; [@bib59]; [@bib66]). B cells may also play an important role in MS via TLR4 and/or TLR2 signaling-mediated alterations in anti-inflammatory interleukin (IL)-10 production ([@bib11]; [@bib35]; [@bib58]), a cytokine utilized by B regulatory cells to inhibit autoimmunity ([@bib17]).

The regulatory mechanisms in B cells that drive innate activity and inflammatory demyelination in MS are poorly understood. TLR2 and TLR4 play critical roles in initiating innate inflammatory responses, and as the only TLR family members expressed at the cell surface of B cells ([@bib38]; [@bib43]), they may be regulated by *N*-glycan branching. Cell surface TLR4 and TLR2, which heterodimerizes with TLR1 or TLR6, are pro-inflammatory via MyD88/IRAK/TRAF6/AP-1/NF-κB, whereas signaling from endosomes is anti-inflammatory via TRIF/IRF3 ([@bib63]; [@bib64]; [@bib67]). Thus, regulating TLR2/4 endocytosis is critical to pro- versus anti-inflammatory innate responses in B cells. CD14 controls lipopolysaccharide (LPS)-induced TLR4 endocytosis and associated anti-inflammatory signaling in myeloid cells ([@bib70]); however, B cells do not express CD14.

The role of *N*-glycan branching in B cells is unknown. Here we report that *N*-glycan branching has a unique dual activity in B cells, suppressing innate activity by dose-dependently promoting TLR2 and TLR4 endocytosis while simultaneously fostering adaptive immunity by being required for optimal surface retention of B cell receptor (BCR) and its co-receptor CD19. *N*-glycan branching reduces B cell-triggered pro-inflammatory T~H~1/T~H~17 differentiation of T cells and inflammatory demyelination in mice.

Results {#sec2}
=======

*N*-Glycan Branching Inhibits Pro-inflammatory TLR4 and TLR2 Signaling in B Cells {#sec2.1}
---------------------------------------------------------------------------------

As *N*-glycan branching regulates the endocytosis of multiple glycoproteins, we hypothesized that branching may regulate TLR4 and TLR2 endocytosis in B cells to control pro- versus anti-inflammatory innate responses. To directly assess this hypothesis, we generated mice with B cell-specific deletion of *Mgat1* or *Mgat2* (i.e., *Mgat1*^*f/f*^*CD19cre*^+/-^ and *Mgat2*^*f/f*^*CD19cre*^+/-^). *Mgat1* deficiency is expected to produce a more severe phenotype than *Mgat2* deficiency, as the former eliminates, whereas the latter only reduces branching ([Figure S1](#mmc1){ref-type="supplementary-material"}A) ([@bib48]; [@bib72]). Indeed, whereas CD19-driven cre-deletion of *Mgat2* had no impact on B cell development, deletion of *Mgat1* completely blocked B cell development ([@bib53]). Therefore, to examine *Mgat1* deficiency in mature peripheral B cells, we utilized *Mgat1*^*f/f*^*/tetO-cre/ROSA-rtTA* mice ([@bib72]), where doxycycline consistently induces *Mgat1* deficiency in ∼35%--40% of mature *ex vivo* splenic B cells. *Mgat1-* and *Mgat2*-deleted B cells (97%--99% pure) were isolated from doxycycline-treated *Mgat1*^*f/f*^*/tetO-cre/ROSA-rtTA* or *Mgat2*^*f/f*^*CD19cre*^+/-^ mice, respectively, by negative selection with *Phaseolus vulgaris* leukoagglutinin (L-PHA)^+^ cell depletion ([Figure S1](#mmc1){ref-type="supplementary-material"}B). L-PHA binds β1,6-branched *N*-glycans, structures that are eliminated by *Mgat1* or *Mgat2* deficiency ([@bib14]). For ease of nomenclature, we refer to these purified cells as *Mgat1*^−/−^ and *Mgat2*^−/−^ B cells in the following discussion. To address any potential complications from doxycycline treatment, we also phenocopied *Mgat1* deletion by treating wild-type B cells with the mannosidase 1 inhibitor kifunensine (KIF). As the Mgat1 enzyme requires mannosidase 1 to remove mannose and initiate GlcNAc branching ([Figure S1](#mmc1){ref-type="supplementary-material"}A), KIF blocks Mgat1 enzyme activity to prevent *N*-glycan branching.

*Mgat1*^−/−^ and *Mgat2*^−/−^ B cells hypo-proliferated in response to both LPS (TLR4 agonist) and the bacterial lipopeptides Pam~2~CSK~4~ (TLR2:6 heterodimer agonist) and Pam~3~CSK~4~ (TLR2:1 heterodimer agonist), as measured by Carboxyfluorescein succinimidyl ester (CFSE) dilution ([Figure 1](#fig1){ref-type="fig"}A). The magnitude of hypo-proliferation was less in *Mgat2*^−/−^ than *Mgat1*^−/−^ B cells, consistent with a less-severe loss of branching in the former. Remarkably, despite hypo-proliferation, up-regulation of the activation marker CD69 induced by TLR4 and TLR2 agonists was enhanced by both *Mgat1* and *Mgat2* deficiency ([Figure 1](#fig1){ref-type="fig"}B). Blocking *N*-glycan branching in wild-type B cells with KIF similarly enhanced CD69 induction by TLR4 and TLR2 agonists ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Consistent with this, pro-inflammatory NF-κB activation by cell surface TLR4 and TLR2 signaling was enhanced by *Mgat1* and *Mgat2* deficiency ([Figure 1](#fig1){ref-type="fig"}C). TLR4 also signals through SYK to activate ERK and AKT ([@bib62]), and branching deficiency led to enhanced LPS-induced SYK, ERK, and AKT phosphorylation ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1E). In contrast, anti-inflammatory endosomal TLR4 signaling via TBK1 and TRAF3 was unchanged by *Mgat1* deficiency ([Figure 1](#fig1){ref-type="fig"}D). NF-κB activation drives secretion of pro-inflammatory tumor necrosis factor (TNF)-α over anti-inflammatory IL-10 ([@bib17]). *Mgat1*^*−/−*^ B cells stimulated with TLR4 or TLR2 agonists displayed increased TNFα and reduced IL-10 secretion compared with control B cells ([Figure 1](#fig1){ref-type="fig"}E). Consistent with this, *Mgat1* and *Mgat2* deletion also greatly reduces the number of endogenous IL-10-producing B10 regulatory B cells *in vivo* ([Figure S1](#mmc1){ref-type="supplementary-material"}F). B cells express the T cell co-stimulatory ligands CD80 and CD86, which promote pro-inflammatory T~H~1 and humoral/immunomodulatory T~H~2 responses, respectively, to influence inflammatory demyelination in EAE ([@bib39]; [@bib71]). CD80 exists as a dimer, whereas CD86 is a monomer ([@bib4]), allowing CD80 to bind CD28 with much greater affinity and thereby drive demyelinating disease ([@bib39]; [@bib71]). LPS-stimulated *Mgat1*^*−/−*^ and *Mgat2*^*−/−*^ B cells displayed increased induction of CD80 and less CD86 on their cell surface compared with controls ([Figure 1](#fig1){ref-type="fig"}F). Induction of MHCII was also elevated in *Mgat1*^*−/−*^ and *Mgat2*^*−/−*^ B cells ([Figure 1](#fig1){ref-type="fig"}G). In contrast, CD80, CD86, and MHCII surface levels on resting B cells were unaltered by *Mgat1* or *Mgat2* deficiency ([Figures S1](#mmc1){ref-type="supplementary-material"}G and S1H). Together, these data demonstrate that *N*-glycan branching inhibits TLR4 and TLR2 pro-inflammatory cell surface signaling in B cells.Figure 1*N*-Glycan Branching Inhibits Pro-inflammatory TLR4 and TLR2 Activation in B Cells(A, B, F, and G) TLR4- and TLR2-stimulated B cells were assessed by flow cytometry for proliferation by CFSE dilution after 2 days (A), CD69 expression after 1 day (B), surface expression of CD80/CD86 after 1--3 days (F), and MHCII after 3 days (G). Histograms in (A and B) represent highest agonist dose.(C and D) Western blot analysis of phospho-NFκB (p65) (C) and total TRAF3 protein and phospho-TBK1 (D) in B cells stimulated for 2 days.(E) TNFα and IL-10 secretion measure by ELISA from culture supernatants of stimulated B cells over 1--3 days.Data shown are mean ± SEM of cells stimulated in triplicate (A, B, E, and F) and representative of n ≥ 3 experiments. Each symbol represents one mouse from three different experiments; horizontal line represents the mean; repeated-measures ANOVA with false discovery rate correction (Benjamini, Krieger, and Yekutieli) for multiple comparisons (G). NS, not significant; ∗p \< 0.05. Divided (%), CFSE dilution by half or more. MFI, mean fluorescence intensity.

*N*-Glycan Branching Suppresses TLR4 and TLR2 Signaling by Enhancing Loss to Endocytosis {#sec2.2}
----------------------------------------------------------------------------------------

Next, we investigated the mechanism for enhanced TLR4 and TLR2 cell surface signaling. In resting B cells, cell surface expression of TLR4 is minimal ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Resting *Mgat1*^*−/−*^ B cells displayed no significant difference in TLR4 or TLR2 surface expression, endocytosis rate, or mRNA levels ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2C). Binding of LPS to cell surface TLR4 was also unaltered by *Mgat1* deficiency, indicating that loss of branching did not impact the interaction of LPS with TLR4 ([Figure S2](#mmc1){ref-type="supplementary-material"}D). However, 2--3 days after TLR4 or TLR2 stimulation, *N*-glycan branching-deficient B cells had greater TLR4 and TLR2 surface expression than control cells, with *Mgat1* \> *Mgat2* deficiency ([Figure 2](#fig2){ref-type="fig"}A). This coincided with a TLR4- or TLR2-induced physiological increase in *N*-glycan branching in activated wild-type B cells ([Figure 2](#fig2){ref-type="fig"}B). Comparing cell surface versus total TLR4 and TLR2 by flow cytometry indicated that loss of branching did not alter total TLR protein levels but specifically enhanced cell surface TLR4 and TLR2 expression ([Figure 2](#fig2){ref-type="fig"}C). Western blotting confirmed that total TLR4 protein was not altered ([Figure S2](#mmc1){ref-type="supplementary-material"}E). Consistent with increased surface levels, the rate of TLR4 and TLR2 endocytosis in activated B cells was significantly reduced by *Mgat1* \> *Mgat2* deficiency ([Figure 2](#fig2){ref-type="fig"}D) as well as blocking branching in wild-type B cells with KIF ([Figure S2](#mmc1){ref-type="supplementary-material"}F). Like mouse B cells, resting human B cells express little TLR4 at the cell surface; however, inflammatory conditions and activation via BCR, CD40, and TLR9 (CpG) induced TLR4 in human B cells ([@bib18]; [@bib36]; [@bib46]; [@bib55]). Consistent with these data and our mouse data, blocking branching in human B cells with KIF enhanced TLR4 surface expression induced by co-stimulation with CpG + CD40L or CpG + anti-IgM/G/A ([Figure S2](#mmc1){ref-type="supplementary-material"}G). Collectively, these data reveal that *N*-glycan branching is markedly up-regulated by TLR4 and TLR2 signaling and serves to inhibit pro-inflammatory TLR4 and TLR2 signaling in activated B cells by enhancing surface loss to endocytosis.Figure 2*N*-Glycan Branching Reduces TLR4 and TLR2 Surface Levels by Promoting Endocytosis(A--D) Flow cytometric analysis of B cells stimulated for 1--3 days and assessed for TLR4 and TLR2 surface expression (A), L-PHA binding (B), TLR4 and TLR2 surface-to-total ratio (C), and TLR4 and TLR2 endocytosis rates (D). Endocytosis rate over 1.5 h was calculated by dividing the MFI of acid-washed cells by the MFI of fluorescence-activated cell sorting (FACS) buffer-washed cells divided by 1.5 h (D). Data shown are mean ± SEM of cells stimulated in triplicate and representative of n ≥ 3 experiments. MFI, mean fluorescence intensity.

*N*-Glycan Branching Promotes BCR Signaling Independently of CD22 via Enhanced BCR and CD19 Surface Retention {#sec2.3}
-------------------------------------------------------------------------------------------------------------

As *N*-glycan branching regulates both basal and ligand-induced TCR signaling, we explored whether branching similarly regulates BCR signaling. *Mgat1*^*−/−*^ B cells hypo-proliferated in response to anti-IgM F(ab')~2~ compared with control B cells ([Figure 3](#fig3){ref-type="fig"}A), a result opposite to that in T cells but similar to TLR4- and TLR2-stimulated B cell proliferation. A potential mechanism for altered BCR signaling in *Mgat1*-deficient B cells is via CD22, a negative regulator of BCR signaling. CD22 is a Siglec (sialic-acid-binding immunoglobulin-like lectin) that binds α2,6-linked sialic acid, a terminal sugar attached to galactose in a wide variety of glycans including *N*-glycans, O-glycans, and glycolipids. CD22-deficient B cells hyper-proliferate in response to anti-IgM F(ab')~2~ by preventing delivery of the phosphatase SHP-1 to BCR ([@bib54]; [@bib57]). Deficiency of ST6Gal-I, the enzyme that generates the CD22 ligand (α2,6-linked sialic acid), promotes association of CD22 with BCR. This interaction promotes BCR endocytosis, inhibits BCR signaling, and reduces B cell proliferation ([@bib10]; [@bib21]; [@bib28]; [@bib32]). As *Mgat1* deficiency eliminates terminal sialic acids on *N*-glycans, but not other glycan types, it is possible that loss of branching may inhibit BCR signaling by promoting association of CD22 with BCR. To assess this hypothesis, we generated *CD22*^*−/−*^*/Mgat1*^*f/f*^*/tetO-cre/ROSA-rtTA* mice, where *Mgat1*^−/−^*CD22*^−/−^ B cells are purified following doxycycline treatment. As previously reported, *CD22*^−/−^ B cells were hyper-proliferative in response to anti-IgM F(ab')~2~. However, eliminating CD22 on *N*-glycan branching-deficient B cells failed to rescue proliferation ([Figure 3](#fig3){ref-type="fig"}A). This is in contrast to ST6Gal-I deficiency, where CD22 loss reversed the negative effects of α2,6-linked sialic acid deficiency on BCR signaling to rescue proliferation ([@bib10]).Figure 3*N*-Glycan Branching Promotes Activation Signaling via CD19 and the B Cell Receptor Independent of CD22(A, B, and D--F) Flow cytometric analysis of anti-IgM F(ab')~2~-induced proliferation by CFSE dilution after 2 days (A) and Ca^2+^ mobilization over 4 min (B), and *ex vivo* B cells for IgM surface expression (D), CD19 surface expression (E), and CD19 endocytosis (F). Histograms in (A) represent highest stimulation concentration, arrow in (B) indicates addition of 2.5 μg/mL anti-IgM F(ab')~2~, and immunofluorescent images in (E) were acquired on an Amnis ImageStream Imaging Flow Cytometer. Endocytosis rate over 1.5 h was calculated by dividing the MFI of acid-washed cells by the MFI of FACS buffer-washed cells divided by 1.5 h (F).(C) Western blot analysis of phospho-CD19, phospho-Syk, and phospho-PLCγ in B cells stimulated with 10 μg/mL anti-IgM F(ab')~2~. Data shown are mean ± SEM of cells stimulated in triplicate (A and F) and representative of n ≥ 3 experiments. Each symbol represents one mouse, and horizontal line represents the mean (D and E). Repeated-measures ANOVA with false discovery rate correction (Benjamini, Krieger, and Yekutieli) for multiple comparisons (D and E) and unpaired two-tailed *t* test (F). NS, not significant; ∗∗∗∗\'p \< 0.0001. MFI, mean fluorescence intensity.

Next, we explored whether *N*-glycan branching directly alters BCR signaling via reductions in surface expression of BCR and/or the CD19 co-receptor. CD19 facilitates the phosphorylation of immunoreceptor tyrosine-based activation motifs on Igα/Igβ at the BCR complex by recruiting the protein kinases Lyn and Syk to initiate signaling cascades including PLCγ/Ca^2+^-dependent proliferation ([@bib13]; [@bib50]). *Mgat1*^*−/−*^ B cells displayed reduced anti-IgM F(ab')~2~ induced Ca^2+^ flux ([Figure 3](#fig3){ref-type="fig"}B) and phosphorylation of CD19, Syk, and PLCγ2 ([Figure 3](#fig3){ref-type="fig"}C). Cell surface levels of IgM were similarly reduced in *Mgat1*^*−/−*^*, CD22*^−/−^, and *Mgat1*^−/−^*CD22*^−/−^ B cells compared with control ([Figure 3](#fig3){ref-type="fig"}D), a phenotype comparable to ST6Gal-I and/or CD22 deficiency ([@bib10]). There was also a reduction in CD22 surface levels in *Mgat1*^*−/−*^ B cells ([Figure S3](#mmc1){ref-type="supplementary-material"}A). However, *Mgat1*^*−/−*^ and *Mgat1*^−/−^*CD22*^−/−^ B cells had markedly reduced surface levels of CD19, whereas *CD22*^−/−^ B cells had no significant difference compared with control ([Figure 3](#fig3){ref-type="fig"}E). Indeed, CD19 surface loss to endocytosis was enhanced by *Mgat1* deficiency ([Figure 3](#fig3){ref-type="fig"}F) and KIF treatment ([Figure S3](#mmc1){ref-type="supplementary-material"}B). There was no difference in CD19 mRNA levels ([Figure S3](#mmc1){ref-type="supplementary-material"}C), whereas total CD19 protein was reduced in *Mgat1*^*−/−*^ B cells ([Figure S3](#mmc1){ref-type="supplementary-material"}D), consistent with protein loss via degradation of endocytosed protein. These results demonstrate that *N*-glycan branching promotes BCR signaling and proliferation by enhancing BCR and CD19 surface expression independent of regulation by CD22.

In contrast to *Mgat1* deficiency and KIF treatment, which completely block all branching, limiting *N*-glycans to a single branch via *Mgat2* deficiency in B cells did not alter anti-IgM F(ab')~2~-induced proliferation, Ca^2+^ mobilization, or IgM and CD19 surface levels ([Figures S3](#mmc1){ref-type="supplementary-material"}E--S3H). In T cells, the reduction in branching induced by *Mgat2* deletion is partially compensated for by poly-N-acetyllactosamine (poly-LacNAc) extension of the remaining single GlcNAc branch, which leads to the same level of cell surface galectin-3 binding and TCR hyper-activity as *Mgat5*^*−/−*^ T cells ([@bib48]). *Mgat2*^*−/−*^ B cells similarly displayed up-regulated poly-LacNAc expression, as measured by flow cytometry with *Lycopersicon esculentum* lectin (LEA) ([Figure S3](#mmc1){ref-type="supplementary-material"}I) ([@bib48]). Together these results demonstrate that a minimal threshold level of LacNAc (galectin ligand) within branched *N*-glycans is required to maintain CD19 at the cell surface and drive robust adaptive immunity BCR responses.

*N*-Glycan Branching Deficiency in B Cells Promotes Pro-inflammatory APC Function {#sec2.4}
---------------------------------------------------------------------------------

As *Mgat2* deficiency impacted innate TLR2 and TLR4, but not adaptive BCR/CD19, responses, we utilized this model to explore the impact of branching on APC function of B cells. LPS-induced up-regulation of MHCII and CD80 in *Mgat2*^−/−^ B cells should increase B cell-triggered T cell activation. To examine this, LPS pre-stimulated and non-LPS pre-stimulated *Mgat2*^−/−^ and control B cells from C57BL/6 mice were co-cultured with wild-type allogeneic splenic CD4^+^ T cells from PL/J mice under neutral, T~H~1-, T~H~17-, or T~REG~-inducing conditions. *Mgat2* branching deficiency in LPS \> non-LPS pre-stimulated B cells markedly enhanced the differentiation of wild-type CD4^+^ T cells to T~H~1 and T~H~17 cells under their respective conditions ([Figure 4](#fig4){ref-type="fig"}A, 4B, [S4](#mmc1){ref-type="supplementary-material"}A, and S4B) while also inhibiting T~REG~ differentiation under T~REG~-inducing conditions ([Figure 4](#fig4){ref-type="fig"}C and [S4](#mmc1){ref-type="supplementary-material"}C). Under neutral conditions, addition of LPS also directly enhanced T~H~1 differentiation by *Mgat2*^−/−^ B cells ([Figure S4](#mmc1){ref-type="supplementary-material"}D). To confirm these results in an antigen-specific *in vitro* model, we utilized congenic 2D2 TCR^MOG^ transgenic mice that harbor CD4^+^ T cells specific for the human MOG~35-55~ peptide (hMOG~35-55~). Relative to control B cells, *Mgat2*^*−/−*^ B cells significantly increased the differentiation of 2D2 CD4^+^ T cells to T~H~1 and T~H~17 cells in response to hMOG~35-55~ ([Figures 4](#fig4){ref-type="fig"}D, 4E, [S4](#mmc1){ref-type="supplementary-material"}E, and S4F), but had little effect on T~REG~ differentiation ([Figure 4](#fig4){ref-type="fig"}F and [S4](#mmc1){ref-type="supplementary-material"}G). LPS pre-treatment was required for enhanced T~H~1 differentiation of 2D2 CD4^+^ T cells by *Mgat2*^*−/−*^ B cells, but was less critical to enhanced T~H~17 differentiation ([Figures S4](#mmc1){ref-type="supplementary-material"}E and S4F). 2D2 CD4^+^ T cell differentiation in response to hMOG~35-55~ was dose dependent ([Figure S4](#mmc1){ref-type="supplementary-material"}H), whereas OVA~323-339~ peptide did not induce robust CD4^+^ T cell responses under any conditions ([Figure S4](#mmc1){ref-type="supplementary-material"}I). Thus, *N*-glycan branching deficiency directly enhances the ability of B cells to induce pro-autoimmune T~H~1 and T~H~17 responses via co-stimulatory APC function.Figure 4*N*-Glycan Branching Deficiency in B Cells Promotes Pro-inflammatory APC Function(A--F) LPS-stimulated B cells were co-cultured with allogeneic CD4^+^ T cells (A--C) or congenic 2D2 TCR transgenic CD4^+^ T cells +2.5 μg/mL hMOG~35-55~ (D--F) under T~H~1/T~H~17/T~REG~-inducing conditions. CD4^+^ T cells were assessed by flow cytometry for intracellular staining of IFNγ after 3 days (A and D) and IL-17A (B and E) and FOXP3 (C and F) after 4 days. Data shown are mean ± SEM of cells stimulated in triplicate and representative of n = 3 experiments. Unpaired one-tailed t tests. NS, not significant; ∗p \< 0.05; ∗∗p \< 0.01.

*N*-Glycan Branching Deficiency in B Cells Promotes Inflammatory Demyelination {#sec2.5}
------------------------------------------------------------------------------

Next, we explored whether the enhanced innate activity induced by *Mgat2* deficiency in B cells promotes inflammatory demyelination in the MS model EAE. As C57BL/6 mice lacking B cells are resistant to EAE induced with whole recombinant human myelin oligodendrocyte glycoprotein protein (rhMOG) but remain sensitive to EAE induced by the MOG~35-55~ peptide and whole recombinant mouse MOG ([@bib17]; [@bib49]), we utilized rhMOG to induce B cell-dependent EAE in *Mgat2*^*f/f*^*CD19cre*^+/-^ and control *CD19cre*^+/-^ C57BL/6 mice. *Mgat2* deficiency in B cells significantly enhanced the incidence and severity of clinical EAE ([Figures 5](#fig5){ref-type="fig"}A--5C) as well as infiltration of the spinal cord by CD4^+^ T cells and B220^+^ B cells ([Figure 5](#fig5){ref-type="fig"}D). To evaluate whether *Mgat2* deletion enhanced B cell APC function to promote induction of T~H~1 and T~H~17 cells *in vivo*, we examined splenocytes isolated from EAE mice. Consistent with our *in vitro* co-culture data, *Mgat2* deficiency in B cells of EAE mice enhanced rhMOG induction of T~H~1 and T~H~17 cells, but not T~REG~ cells, *in vivo* ([Figure 5](#fig5){ref-type="fig"}E).Figure 5*N*-Glycan Branching Deficiency in B Cells Promotes Inflammatory Demyelination(A--C) EAE was induced in 8- to 12-week-old congenic C57BL/6 mice with day 0 indicating the time of immunization and clinical score (A), disease incidence (B), and highest clinical score (C) monitored over 35 days (n = 12 (F7,M5) *CD19cre*^+/-^, n = 11 (F6,M5) *Mgat2*^*f/f*^*CD19cre*^+/-^).(D and E) On day 35, mice induced with EAE were used for flow cytometric analysis of infiltrating CD4^+^ T cell and B220^+^ B cell in spinal cords (D) and *in vivo* cytokine production of splenic CD4^+^ T cells (E). Each symbol represents one mouse; horizontal line represents the mean.Two-way ANOVA (A and B) and unpaired one-tailed t tests (C--E). NS, not significant; ∗p \< 0.05; ∗∗p \< 0.01.

Discussion {#sec3}
==========

B cells play an important role in MS pathogenesis ([@bib30], [@bib31]). Here we identify *N*-glycan branching as a regulatory mechanism in B cells that decouples innate pro-inflammatory cell surface TLR function from adaptive activity via BCR/CD19, the former negatively regulating B cell APC-induced pro-inflammatory T~H~1/T~H~17 T cell responses and demyelinating disease ([Figure 6](#fig6){ref-type="fig"}). *N*-glycan branching is markedly increased by TLR4 and TLR2 signaling, which titrates reductions in surface expression of TLR4 and TLR2 via endocytosis over a broad continuum. In contrast, a single GlcNAc branch maximizes BCR and CD19 retention at the cell surface to drive adaptive immune responses, with higher levels of branching having no additional impact. The APC function of B cells is inhibited by *N*-glycan branching in part via suppression of TLR4 and TLR2 signaling-induced up-regulation of MHCII, CD80, and pro-inflammatory cytokines. Co-suppression of MHCII and CD80 by *N*-glycan branching reduces both primary TCR signaling as well as co-stimulatory signals via CD28, thereby inhibiting B cell triggered pro-inflammatory T~H~1/T~H~17 responses and inflammatory demyelination.Figure 6N-glycan Branching Decouples Endocytosis of Surface TLR and CD19/BCR to Suppress Innate and Promote Adaptive ImmunityBranching in B cells promotes endocytic loss of surface TLR (TLR4 and TLR2) to suppress ligand-induced surface TLR signaling and downstream APC activity in B cells via reductions in MHCII, CD80 over CD86 and pro-inflammatory TNFa, which in turn inhibits B cell-dependent CD4^+^ T~H~1/T~H~17 differentiation and inflammatory demyelination. Concurrently, branching promotes CD19/BCR surface-retention to drive Ca^2+^ flux and proliferation in response to BCR ligands, thereby promoting adaptive B cell function. While intermediate reductions in branching enhance surface TLR signaling, CD19/BCR surface expression/signaling is not impacted. Rather, complete absence of branched N-glycans is required to drive CD19 endocytosis and inhibit BCR responses. Thus, the impact of branching on TLR/APC activity occurs over a large continuum, whereas a minimal level of branching is sufficient to promote BCR responses. Figure created with Biorender.com.

B cell depletion with anti-CD20 antibodies inhibits relapses and progression in MS, a blunt tool that non-specifically reduces both innate and adaptive immunity. In contrast, enhancing *N*-glycan branching in B cells may provide a safer therapeutic strategy by suppressing APC function and innate immunity while maintaining adaptive immunity via BCR/CD19. In this regard, we have previously demonstrated that metabolically supplementing T cells with the simple sugar N-acetylglucosamine (GlcNAc) increases *N*-glycan branching via enhanced substrate supply to the Golgi (Mgat) branching enzymes ([@bib1]; [@bib24]; [@bib40]; [@bib42]; [@bib47]). GlcNAc is orally active, and when fed to mice, it suppresses pro-inflammatory T cell responses *in vivo* and inhibits/treats EAE and autoimmune diabetes ([@bib24], [@bib22]). Based on this activity, we are currently conducting a dose-finding Phase 1 clinical trial of GlcNAc in MS. Our data on B cells raise the possibility that in addition to direct effects on T cells, oral GlcNAc may also function to suppress inflammatory demyelination by raising branching in B cells *in vivo*. Further investigations are warranted to characterize branching/poly-LacNAc expression of B cells in patients with MS, and determine the effects of GlcNAc on B cell activity.

In myeloid cells, CD14 controls TLR4 endocytosis to regulate pro-inflammatory (cell surface) versus anti-inflammatory (endosomal) signaling ([@bib70]). As B cells lack CD14, how TLR4 cell surface versus endosomal signaling is regulated in B cells was poorly understood. Our data identify *N*-glycan branching in activated B cells as a critical determinant of pro- versus anti-inflammatory TLR4 signaling. Conditions that drive low branching would be expected to trigger TLR4 surface expression and innate pro-inflammatory B cell activity. This has implications for a wide diversity of inflammatory conditions where B cell innate activity is critical. Whether branching also regulates TLR4/2 surface expression in other APCs requires further investigation.

In contrast to promoting TLR4/2 endocytosis, *N*-glycan branching inhibits CD19 endocytosis to support BCR signaling and downstream adaptive immunity. *N*-glycan branching--galectin interactions regulate the segregation of transmembrane glycoproteins to different membrane microdomains, such as endocytic pits, by opposing the movement driven by intra-cellular actin-microfilament networks ([@bib9]). This molecular mechanism likely explains how *N*-glycan branching simultaneously enhances TLR4/TLR2, but inhibits CD19 endocytosis. If actin tethering to cytoplasmic domains drives a glycoprotein to endocytic pits, *N*-glycan branching (galectin lattice) opposes this to inhibit endocytosis. However, if actin has the opposite effect on a glycoprotein and drives it away from endocytic pits, then *N*-glycan branching would oppose this and promote endocytosis. In unpublished data using a cell surface whole proteome mass-spectrometric analysis of T cells, we observed that of 208 transmembrane proteins identified, 71 were reduced at the cell surface without *N*-glycan branching, whereas 27 were increased. These results were confirmed by flow cytometry, with 11 of 13 replicated (6 down, 5 up). Thus, the opposing effects of *N*-glycan branching on TLR and CD19 are not unique; however, additional experiments are required to further delineate molecular details.

Although *N*-glycan branching deficiency in B cells augments TLR2/TLR4 surface expression and pro-inflammatory signaling, LPS-induced proliferation was reduced. CD19 plays an important role in LPS-induced proliferation, with CD19 knockout inhibiting and CD19 over-expression enhancing LPS-induced B cell proliferation ([@bib16]). Consistent with this, the marked reduction in CD19 induced by *Mgat1* deficiency is associated with reduced LPS-triggered proliferation. In contrast, *Mgat2* deficiency has little impact on CD19 surface levels and LPS-induced proliferation is only marginally impacted in *Mgat2*^−/−^ B cells. Poly-LacNAc extension of *N*-glycans is markedly increased in *Mgat2*^*−/−*^ B cells, which serves to enhance galectin avidity and thereby likely contributes to maintaining surface CD19 and signaling similar to control. Capping branched *N*-glycans with α2,6-sialic acid also inhibits galectin binding ([@bib73]), and this may be another important contributor to the regulation of TLR2/4 versus CD19 surface retention.

Human naive, germinal center (GC), and memory B cells express bi-, tri-, and tetra-antennary complex *N*-glycans containing poly-LacNAc, thereby promoting binding of galectin-9 to BCR and inhibiting BCR signaling ([@bib7]; [@bib19]). *Mgat2* deficiency induces loss of bi-, tri-, and tetra-antennary branched *N*-glycans, but concurrent up-regulation of poly-LacNAc expression serves to maintain galectin ligand availability ([@bib48]). Thus, *Mgat2* deficiency should have little impact on galectin-9-mediated suppression of BCR signaling, which is consistent with the lack of altered BCR signaling observed in *Mgat2*^*−/−*^ B cells. In contrast, *Mgat1* deficiency eliminates both branching and poly-LacNAc and is expected to prevent binding of galectin-9 and enhance BCR signaling. However, the dramatic reduction in BCR and CD19 surface expression induced by *Mgat1* (but not *Mgat2*) deficiency is dominant, thereby reducing BCR signaling despite a potential decrease in galectin-9 binding to BCR. Consistent with this, we recently observed that deleting *Mgat1* in pro/pre-bone-marrow B cells completely blocks development of mature B cells by reducing CD19/BCR signaling ([@bib53]).

The effects of branching on TLR4 surface retention were greater than TLR2. This may be explained by differences in the number of attached N-glycosylation sites, which also determines interaction with galectins ([@bib40]). TLR4 has 14 and TLR2 has 3. The TLR2 binding partners TLR1 and TLR6 have 9 and 10, respectively. When respective agonists bind, these TLRs dimerize to form TLR4:4 with 28, TLR2:1 with 12, and TLR2:6 with 13 combined N-glycosylation sites, respectively. Thus, TLR4:4 homodimers have more than double the number of *N*-glycans, making the consequences for complete loss of *N*-glycan branching more severe than that of TLR2:1 or TLR2:6 heterodimers.

Others have reported that loss of BCR inhibits LPS-induced Syk activation in short-term signaling assays (i.e., 15 minutes) ([@bib62]). In contrast, we observed that *Mgat1* deficiency enhanced Syk activation following 2 days of LPS stimulation despite the concurrent reduction in BCR and CD19 surface levels. The reason for this difference requires further investigation, but our data suggest that the gain of TLR4 surface levels in blasting B cells is dominant over negative regulation of Syk activation from reduced BCR/CD19.

Limitations of the Study {#sec3.1}
------------------------

There are several limitations of this study. First, although we confirmed that reducing *N*-glycan branching in human B cells similarly up-regulated TLR4 surface expression, we did not examine the functional consequences in human B cells. Second, we did not directly examine whether patients with MS have alterations in *N*-glycan branching that result in altered innate B cell function. Such studies require highly characterized cohorts of patients who are not on treatment, as the latter would impact our ability to assess immune function. Third, the precise mechanism by which *N*-glycan branching promotes TLR2/4 endocytosis while inhibiting CD19 endocytosis is not well defined. Given our results in T cells on the mechanism by which *N*-glycan branching differentially regulates TCR versus CD45 segregation to membrane microdomains, it is likely that different cytoplasmic microfilament tethers to TLR2/4 versus CD19 direct these proteins away from or toward endocytic pits, respectively, with *N*-glycan branching/galectin lattice opposing this force. Additional experiments will be required to investigate this hypothesis.

Resource Availability {#sec3.2}
---------------------

### Lead Contact {#sec3.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact Michael Demetriou (<mdemetri@uci.edu>).

### Materials Availability {#sec3.2.2}

All unique reagents/mice generated in this study will be made available on request, but may require a completed Materials Transfer Agreement.

### Data and Code Availability {#sec3.2.3}

This study did not generate/analyze \[datasets/code\].

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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